3,188 Shares in Apogee Therapeutics, Inc. (NASDAQ:APGE) Acquired by Kennedy Capital Management LLC

Kennedy Capital Management LLC purchased a new stake in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 3,188 shares of the company’s stock, valued at approximately $212,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in Apogee Therapeutics by 60.7% during the 1st quarter. Vanguard Group Inc. now owns 1,868,666 shares of the company’s stock valued at $124,173,000 after purchasing an additional 705,795 shares during the period. Wellington Management Group LLP increased its holdings in shares of Apogee Therapeutics by 0.3% in the fourth quarter. Wellington Management Group LLP now owns 1,591,478 shares of the company’s stock valued at $44,358,000 after purchasing an additional 4,749 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Apogee Therapeutics by 51.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,170,327 shares of the company’s stock valued at $77,770,000 after buying an additional 399,646 shares in the last quarter. Franklin Resources Inc. boosted its holdings in Apogee Therapeutics by 9.3% in the 4th quarter. Franklin Resources Inc. now owns 1,089,780 shares of the company’s stock valued at $30,448,000 after purchasing an additional 92,423 shares during the period. Finally, Darwin Global Management Ltd. acquired a new position in Apogee Therapeutics in the first quarter valued at about $55,300,000. Institutional investors own 79.04% of the company’s stock.

Insider Activity at Apogee Therapeutics

In other Apogee Therapeutics news, insider Carl Dambkowski sold 5,995 shares of the stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $37.60, for a total transaction of $225,412.00. Following the completion of the transaction, the insider now owns 294,793 shares of the company’s stock, valued at $11,084,216.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Michael Thomas Henderson sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, July 5th. The shares were sold at an average price of $37.26, for a total transaction of $558,900.00. Following the transaction, the chief executive officer now directly owns 1,474,487 shares in the company, valued at $54,939,385.62. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Carl Dambkowski sold 5,995 shares of the firm’s stock in a transaction that occurred on Wednesday, July 3rd. The shares were sold at an average price of $37.60, for a total value of $225,412.00. Following the completion of the sale, the insider now directly owns 294,793 shares of the company’s stock, valued at $11,084,216.80. The disclosure for this sale can be found here. 36.10% of the stock is currently owned by insiders.

Apogee Therapeutics Stock Performance

NASDAQ APGE opened at $45.75 on Friday. Apogee Therapeutics, Inc. has a 1-year low of $14.19 and a 1-year high of $72.29. The business has a 50 day simple moving average of $43.70 and a two-hundred day simple moving average of $46.95.

Apogee Therapeutics (NASDAQ:APGE) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.04). As a group, equities analysts anticipate that Apogee Therapeutics, Inc. will post -2.64 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on APGE shares. Wedbush restated an “outperform” rating and issued a $87.00 price target on shares of Apogee Therapeutics in a research report on Monday, May 13th. Bank of America started coverage on shares of Apogee Therapeutics in a report on Friday, May 10th. They set a “buy” rating and a $80.00 price objective on the stock. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $73.00.

Apogee Therapeutics Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.